NCT04793659 - Fasudil fOr redUcing elopemeNt and Spatial Disorientation | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

December 15, 2020

Primary Completion Date

December 8, 2021

Study Completion Date

February 11, 2022

Conditions

Dementia

Interventions

DRUG

Oral Fasudil 90 mg/day

Oral tablet

DRUG

Oral Fasudil 180 mg/day

Oral tablet

DRUG

Oral Placebo

Oral tablet

Trial Locations (11)

Barwon Geriatrics, Geelong

GV Health, Shepparton

Northeast Health Wangaratta, Wangaratta

Modbury Hospital, Modbury

Neurodegenerative Disorders Research, West Perth

Re:Cognition Health, Fairfax

Lakes Research, LLC., Miami Lakes

Accel Research Sites, Lakeland

Albuquerque Neuroscience Inc., Albuquerque

New England Institute for Clinical Research, Stamford

Bio Behavioral Health, Toms River